Navigation Links
Butamax Announces Immediate Appeal of Court Decisions on Claim Construction and Summary Judgment
Date:3/20/2013

WILMINGTON, Del., March 20, 2013 /PRNewswire/ -- Butamax™ Advanced Biofuels, LLC, the leading biobutanol technology company, announced today it would appeal the Court's claim construction and decisions on certain motions before the Court in Butamax's litigation against Gevo.

Paul Beckwith , Butamax Chief Executive Officer, stated, "Butamax has decided to appeal this case immediately.  Butamax strongly disagrees with the Court's claim construction.  We do not believe it is consistent with either the patent, rules for patent claim construction or statements made by the Federal Circuit.  We have therefore decided to appeal immediately to resolve this matter before going to trial.  We are confident the Federal Circuit will determine this matter in our favor."

The Court made no overall determination on literal infringement and denied Gevo's motions of invalidity on all but two of 37 patent claims being asserted by Butamax against Gevo.  However, despite previous statements from the Federal Circuit, the Court chose a very narrow claim construction for the KARI enzyme element of the claims.  This narrow interpretation, in Butamax's view, is in error as a matter of law and therefore Butamax is taking this claim construction immediately back to the Federal Circuit for appeal.

Beckwith continues, "This is still an early stage in what is likely to be a long and complicated litigation, involving many patents that will take several years for the courts to resolve.   Butamax is currently enforcing six other patents against Gevo and will vigorously continue to do so while this case is appealed."

Butamax remains strongly committed to near term commercialization of its biobutanol technology.  Butamax will continue its strategy of bringing advanced biofuels to the consumer and providing a real solution to the blendwall.

About Butamax&
'/>"/>

SOURCE Butamax Advanced Biofuels, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Butamax™ Responds to Gevo Patent Infringement Lawsuit
2. Butamax™ and Fagen Announce Collaboration to Retrofit Ethanol Plants for Biobutanol Production
3. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
4. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
5. USPTO Grants Butamax a Further KARI Enzyme Patent
6. Gevo Doesnt Infringe Butamaxs 017 Patent; Gevo was First to Invent Enzyme in 017 Patent; Gevo has Advanced Beyond That and Now Uses Different Enzymes
7. Appeal Courts Direction on Claim Construction Is Strategically Important for Butamaxs Case Against Gevo Scheduled for April 2013
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
9. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
10. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
11. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014  ARCH Venture Partners, one ... in the development of seed and early-stage advanced ... fund closed with more than $400 million in ... million subscription target by more than $150 million. ... the strength and potential of our approach to ...
(Date:8/27/2014)... August 27, 2014 After the boom ... that the next beverage craze is going to be ... that formulators can use Stress Relief energy pattern which ... the making of a beverage, including minerals, herbs and ... energy, channeling that power into rapid recovery and helping ...
(Date:8/27/2014)... Budding Biomedical Scientists , This ... participated in the Scientific Enrichment and Opportunity ... of Medicine . , The rigorous ... experience in the sciences and brings them in ... students for both academic and career mentoring. , ...
(Date:8/26/2014)... An analysis by Replikins, Ltd. of Pubmed data of ... virus strains has revealed extensive conservation and sharing of ... sharing of specific Replikin gene structures has permitted the ... did for the H5N1 influenza vaccine and the Taura ... to be effective (1,2). This ...
Breaking Biology Technology:Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2
... NEW YORK and MONTREAL, Dec. 21 /PRNewswire-FirstCall/ - ICBS Ltd. ... state and municipal regulatory bodies for the sale of the ... Solutions will be moving to target regulatory agencies in the ... advantages not only on time advantage (10 Hours for test ...
... III trials of OGX-011 in first- and second-line advanced ... begin in 2010 and early 2011 -- , -- ... to target resistance to cancer treatments -- , JERUSALEM, ... - Teva Pharmaceutical Industries Ltd. ( TEVA) and OncoGenex ...
... , , THOUSAND OAKS, Calif., Dec. ... Roger M. Perlmutter, M.D., Ph. D., Amgen,s executive vice ... Fellow of the American Association for the Advancement of Science ... on behalf of the advancement of science or its applications ...
Cached Biology Technology:BioSpec Global Solutions Inc. target market TOGS 9000 to state and municipal regulatory bodies in U.S. market 2Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 2Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 3Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 4Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 5Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 6Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 7Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 8Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines 2Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines 3
(Date:8/27/2014)... as giant, frightening beasts. But every creature is a ... slab containing fossils of 24 very young dinosaurs and ... hatchlings overseen by a caretaker, according to a new ... P. Hedrick and Peter Dodson led the work, collaborating ... where the specimen is held. Hedrick is a doctoral ...
(Date:8/27/2014)... that a deficiency in serotonin a chemical messenger ... depression. In the journal ACS Chemical Neuroscience , ... serotonin in their brains (and thus should have been ... , Donald Kuhn and colleagues at the John ... School of Medicine note that depression poses a major ...
(Date:8/27/2014)... have shown that excessive iron is closely ... Previous studies from Chunyan Guo and co-workers ... shown that baicalin prevented iron accumulation after ... 1 expression, and increased ferroportin 1 expression ... disease rats. However, the relationship between iron ...
Breaking Biology News(10 mins):Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3New study throws into question long-held belief about depression 2
... at the U.S. Department of Energy,s Lawrence Berkeley National ... into wispy nanoscale ropes that approach the structural complexity ... development in the push to develop self-assembling nanoscale materials ... but which are rugged enough to withstand harsh conditions ...
... Energy,s Pacific Northwest National Laboratory has been recognized for ... The award-winning partnerships are helping analyze trace amounts of ... and more easily study live cells., The Federal Laboratory ... 2011 for Excellence in Technology Transfer. The consortium is ...
... have proven that you don,t have to travel to exotic ... distinctive species of crayfish in Tennessee and Alabama that is ... genetic relative, once thought to be the only species in ... in Kentucky, can grow almost as big as a lobster. ...
Cached Biology News:A nanoscale rope, and another step toward complex nanomaterials that assemble themselves 2A nanoscale rope, and another step toward complex nanomaterials that assemble themselves 3PNNL recognized for technology transfer 2PNNL recognized for technology transfer 3Researchers discover giant crayfish species right under their noses 2Researchers discover giant crayfish species right under their noses 3Researchers discover giant crayfish species right under their noses 4
... ( Abpromise for all tested applications). ... conjugated to KLH derived from within residues ... 1.(Note: the amino acid sequence is proprietary)(Peptide ... Entrez GeneID: 1822 ...
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
BI-1 Polyclonal Antibody Storage Temperature: -20C Shipping: gel pack Shelf-Life: 12 months...
RAW; Collected from 8-12 week old sexually mature mice that are free of common parasites; RAW Collected from 8-12 week old sexually mature mice that are free of common parasites....
Biology Products: